https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1081)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1081)2016-06-05 12:10:062019-07-17 12:10:27Impact of CD8 stromal lymphocytes in BC patients with the addition of autologous dendritic CELL vaccination to neoadjuvant chemotherapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 3090)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 3090)2016-06-05 11:38:422019-07-17 11:39:065-year follow up for 72 metastatic melanoma patients treated with eltrapuldencel-T (CLBS20) vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-04 / J Clin Oncol 34, 2016 (suppl; abstr 2039)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-04 / J Clin Oncol 34, 2016 (suppl; abstr 2039)2016-06-04 12:03:342019-07-17 12:03:56Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / J Clin Oncol 34, 2016 (suppl; abstr e14579)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / J Clin Oncol 34, 2016 (suppl; abstr e14579)2016-06-03 00:00:002016-06-03 00:00:00A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / J Clin Oncol 34, 2016 (suppl; abstr e14586)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / J Clin Oncol 34, 2016 (suppl; abstr e14586)2016-06-03 00:00:002016-06-03 00:00:00Dendritic cell vaccine transduced with ubiquitin-mesothelin fusion gene for pancreatic cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / BJU Int. 2016 10;118(4):506-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / BJU Int. 2016 10;118(4):506-142016-06-03 00:00:002019-02-15 08:52:00Recent advances in immuno-oncology and its application to urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-452016-06-01 00:00:002016-06-01 00:00:00Emerging immunotherapies for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-31 / J Gynecol Oncol 2016 Sep;27(5):e51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-31 / J Gynecol Oncol 2016 Sep;27(5):e512016-05-31 00:00:002019-02-15 08:35:39Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-31 / Oncoimmunology 2016 Jul;5(7):e1191732
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-31 / Oncoimmunology 2016 Jul;5(7):e11917322016-05-31 00:00:002020-11-30 10:28:30Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-862016-05-07 00:00:002019-02-15 08:39:08Dendritic cell-based cancer immunotherapy for colorectal cancer
